Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Corcept Therapeutics Incorporated

3 Biotech Stocks With Sky-High Price Targets

The biotech sector is primed for growth, fueled by numerous advancements in genetic engineering and rising investment in research and development of personalized medicine. Hence, quality biotech stocks, BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), and Corcept Therapeutics (CORT) with sky-high price targets might be solid buys. Read more….

StockNews.com

3 Biotech Stocks for Investing in the Future

The biotech sector is primed for robust expansion fueled by the growing needs for personalized medicines and favorable government initiatives. Amid this backdrop, investors could consider buying biotech stocks Esperion Therapeutics (ESPR), Corcept Therapeutics (CORT), and Shionogi (SGIOY). Keep reading.

StockNews.com

3 Promising Biotech Stocks Driving Weekly Gains

The biotech industry’s prospects appear promising due to government support, regulatory changes, innovative therapies, and a focus on personalized medicine. Therefore, investors could consider buying fundamentally strong biotech stocks such as United Therapeutics (UTHR), TRACON Pharmaceuticals (TCON), and Corcept Therapeutics (CORT). Read more.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Top 3 Biotech Stocks to Anchor Your Portfolio

Amid robust global medicine spending, surging biopharma M&A activity, and technological advancements, the biotech industry is set for significant growth this year and beyond. Given the industry’s bright prospects, top biotech stocks Corcept Therapeutics (CORT), Entrada Therapeutics (TRDA), and Exelixis (EXEL) might be ideal buys now to anchor one’s portfolio.…

StockNews.com

Plunge into Profits With These 3 Biotech Stocks

The biotech industry's robust growth potential is driven by substantial pharma research and development, swift technological advancements, and lucrative government support. Given this backdrop, quality biotech stocks ProQR Therapeutics N.V. (PRQR), Regeneron Pharmaceuticals (REGN), and Corcept Therapeutics (CORT) could be solid buys now. Read on….

StockNews.com

Elite 4 Biotech Stocks to Buy Now for Explosive Returns

With a wide range of applications across sectors, including health, agriculture, and industrial processing, rapid technological adoption, and government support, the biotech industry’s prospects appear promising. Thus, investors could consider buying biotech stocks Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Incyte (INCY), and Exelixis (EXEL) for substantial gains. Read on….

StockNews.com

3 Biotech Stocks to Buy for Investor Security

Despite macroeconomic challenges, the biotech industry thrives on innovation, demand, and technological breakthroughs. Therefore, fundamentally strong biotech stocks ANI Pharmaceuticals (ANIP), Vanda Pharmaceuticals (VNDA) and Corcept Therapeutics (CORT) might be ideal additions to your portfolio. Read on.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 A-Rated Biotech Stocks for Your 2024 Portfolio

Inelastic demand for healthcare products and services and the increasing government initiatives around the world are expected to boost the biotech industry. Therefore, it could be wise to buy fundamentally strong biotech stocks Entrada Therapeutics (TRDA), Corcept Therapeutics (CORT), and Alkermes (ALKS) this year. Read more.

StockNews.com

Investors Keeping a Close Eye on These 3 Biotech Stocks

Growing adoption of AI technologies by biopharmaceutical companies and growing foothold of personalized medicine are expected to drive growth in the biotech market. Therefore, it could be wise to buy fundamentally strong biotech stocks Regeneron Pharmaceuticals (REGN), Corcept Therapeutics (CORT), and Incyte (INCY). Read more.

StockNews.com

Unlocking Biotech's Potential With 3 Stocks to Buy

The biotech industry’s growth is propelled by strong demand for medical support and interventions, favorable government initiatives, and rapid adoption of emerging technologies. Given the industry’s tailwinds, quality biotech stocks Shionogi (SGIOY), United Therapeutics (UTHR), and Corcept Therapeutics (CORT) could be ideal buys now. Read on….

StockNews.com

Time to Capitalize on These 3 Hot Biotech Stocks

The biotech industry is well-positioned for growth thanks to rising demand for quality healthcare, the prevalence of chronic diseases, and the government’s push to boost domestic biotech production and research. To that end, it could be wise to buy fundamentally strong biotech stocks Corcept Therapeutics (CORT), Ligand Pharmaceuticals (LGND), and…

StockNews.com

Are These 3 Biotech Stocks Good Buys?

Given that the biotech sector is rapidly expanding with robust demand, technology advancements, and government initiatives, fundamentally strong biotech stocks Incyte (INCY), Corcept Therapeutics (CORT), and Entrada Therapeutics (TRDA) look poised to generate significant returns. Hence, these stocks could be solid additions to your portfolio. Read on.

StockNews.com

Top 3 Biotech Stocks with Breakout Potential

The biotech industry is well-positioned to witness significant growth due to technological advancements and government spending. Moreover, given the sector’s defensive nature, biotech stocks Amicus Therapeutics (FOLD), Corcept Therapeutics (CORT), and Harmony Biosciences (HRMY) might be solid buys in 2023. Read on.

StockNews.com

People

Kritika SarmahHer

727 stories

Dipanjan BanchurSince

722 stories

Neha PanjwaniFrom

97 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

FDA

5,706 stories

1,297 stories

the European Commission

Regeneron Pharmaceuticals

Jazz Pharmaceuticals plc

44 stories

Regeneron Pharmaceuticals Inc

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.